JP2007506761A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007506761A5 JP2007506761A5 JP2006528207A JP2006528207A JP2007506761A5 JP 2007506761 A5 JP2007506761 A5 JP 2007506761A5 JP 2006528207 A JP2006528207 A JP 2006528207A JP 2006528207 A JP2006528207 A JP 2006528207A JP 2007506761 A5 JP2007506761 A5 JP 2007506761A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- methyl
- dimethylsuccinyl
- hydrogen
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 40
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- -1 carboxyalkoxymethyl Chemical group 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 230000037396 body weight Effects 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims 5
- 239000003443 antiviral agent Substances 0.000 claims 4
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims 4
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims 4
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 claims 4
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims 4
- 206010038997 Retroviral infections Diseases 0.000 claims 3
- 125000005042 acyloxymethyl group Chemical group 0.000 claims 3
- 125000004849 alkoxymethyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- GTBVPNLDJICROQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one;guanidine Chemical compound NC(N)=N.C1=CC=C2NC(O)=NC2=C1 GTBVPNLDJICROQ-UHFFFAOYSA-N 0.000 claims 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 2
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000003996 Interferon-beta Human genes 0.000 claims 2
- 108090000467 Interferon-beta Proteins 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 2
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims 2
- DLGSOJOOYHWROO-WQLSENKSSA-N [(z)-(1-methyl-2-oxoindol-3-ylidene)amino]thiourea Chemical compound C1=CC=C2N(C)C(=O)\C(=N/NC(N)=S)C2=C1 DLGSOJOOYHWROO-WQLSENKSSA-N 0.000 claims 2
- 229960004748 abacavir Drugs 0.000 claims 2
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 2
- 229960004150 aciclovir Drugs 0.000 claims 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- 229960003805 amantadine Drugs 0.000 claims 2
- 229960001830 amprenavir Drugs 0.000 claims 2
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims 2
- 210000004102 animal cell Anatomy 0.000 claims 2
- 230000005540 biological transmission Effects 0.000 claims 2
- 229960005319 delavirdine Drugs 0.000 claims 2
- 229960002656 didanosine Drugs 0.000 claims 2
- 239000005546 dideoxynucleotide Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229960003804 efavirenz Drugs 0.000 claims 2
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims 2
- 210000003754 fetus Anatomy 0.000 claims 2
- 229960005102 foscarnet Drugs 0.000 claims 2
- 108010074605 gamma-Globulins Proteins 0.000 claims 2
- 229960002963 ganciclovir Drugs 0.000 claims 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 2
- 229960001438 immunostimulant agent Drugs 0.000 claims 2
- 239000003022 immunostimulating agent Substances 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 229960001936 indinavir Drugs 0.000 claims 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 229960001388 interferon-beta Drugs 0.000 claims 2
- 229960001627 lamivudine Drugs 0.000 claims 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 2
- 229960004525 lopinavir Drugs 0.000 claims 2
- 229960003152 metisazone Drugs 0.000 claims 2
- 229960000884 nelfinavir Drugs 0.000 claims 2
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims 2
- 229960000689 nevirapine Drugs 0.000 claims 2
- 230000032696 parturition Effects 0.000 claims 2
- 150000003212 purines Chemical class 0.000 claims 2
- 150000003230 pyrimidines Chemical class 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 229960000329 ribavirin Drugs 0.000 claims 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 2
- 229960001225 rifampicin Drugs 0.000 claims 2
- 229960000311 ritonavir Drugs 0.000 claims 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 2
- 229960001852 saquinavir Drugs 0.000 claims 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 229960001203 stavudine Drugs 0.000 claims 2
- 229960004556 tenofovir Drugs 0.000 claims 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 2
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 229960002555 zidovudine Drugs 0.000 claims 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 2
- UBLNLUPLUKPSPP-UHFFFAOYSA-N 3-beta-form-3-Lupanol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(C)C)C5C4CCC3C21C UBLNLUPLUKPSPP-UHFFFAOYSA-N 0.000 claims 1
- CBMYJHIOYJEBSB-YSZCXEEOSA-N 5alpha-androstane-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 CBMYJHIOYJEBSB-YSZCXEEOSA-N 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- PSZDOEIIIJFCFE-UHFFFAOYSA-N Oleanolic alcohol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C)(C)CC5C4=CCC3C21C PSZDOEIIIJFCFE-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 1
- 125000005096 aminoalkylaminocarbonyl group Chemical group 0.000 claims 1
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 claims 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 claims 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 1
- PSZDOEIIIJFCFE-OSQDELBUSA-N erythrodiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PSZDOEIIIJFCFE-OSQDELBUSA-N 0.000 claims 1
- HTZRWCSRPTWJCT-UHFFFAOYSA-N erythrodiol Natural products CC1(C)CCC2(CO)CCC3C(CCC4C3(C)CCC5C(C)(C)C(O)CCC45C)C2C1 HTZRWCSRPTWJCT-UHFFFAOYSA-N 0.000 claims 1
- 229930183009 gymnemic acid Natural products 0.000 claims 1
- 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 claims 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 claims 1
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 0 CC(C)([C@](CC1)O*)[C@]([C@@](*)C2)[C@@]1(*)[C@@]1[C@]2(*)[C@](C)(CC(C(*)(CCC(*)(*)C2*)[C@@]22N)N)C2=CC1 Chemical compound CC(C)([C@](CC1)O*)[C@]([C@@](*)C2)[C@@]1(*)[C@@]1[C@]2(*)[C@](C)(CC(C(*)(CCC(*)(*)C2*)[C@@]22N)N)C2=CC1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50589903P | 2003-09-26 | 2003-09-26 | |
| US55935804P | 2004-04-05 | 2004-04-05 | |
| PCT/US2004/031370 WO2005030790A1 (en) | 2003-09-26 | 2004-09-27 | Novel triterpene derivatives, preparation thereof and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007506761A JP2007506761A (ja) | 2007-03-22 |
| JP2007506761A5 true JP2007506761A5 (https=) | 2007-11-15 |
Family
ID=34396277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006528207A Withdrawn JP2007506761A (ja) | 2003-09-26 | 2004-09-27 | 新規なトリテルペン誘導体、その製法および使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050148561A1 (https=) |
| EP (1) | EP1675866A1 (https=) |
| JP (1) | JP2007506761A (https=) |
| KR (1) | KR20060096147A (https=) |
| AU (1) | AU2004276307A1 (https=) |
| BR (1) | BRPI0415023A (https=) |
| CA (1) | CA2540160A1 (https=) |
| IL (1) | IL174317A0 (https=) |
| NO (1) | NO20061792L (https=) |
| WO (1) | WO2005030790A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1730163A4 (en) * | 2004-03-17 | 2009-12-30 | Panacos Pharmaceuticals Inc | Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid |
| EP1868613B1 (en) * | 2005-04-12 | 2012-03-07 | Myrexis, Inc. | Polymorphs of 3-o-(3',3'-dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine |
| EP1893629A4 (en) * | 2005-06-22 | 2008-12-17 | Myriad Genetics Inc | ANTIVIRAL CONNECTIONS |
| GB0604899D0 (en) * | 2006-03-10 | 2006-04-19 | York Pharma Plc | Derivatives of 18-glycyrrhetinic acid |
| US20080039428A1 (en) * | 2006-06-29 | 2008-02-14 | Panacos Pharmaceuticals, Inc. | Antiretroviral combination therapy |
| WO2008115281A2 (en) * | 2006-10-16 | 2008-09-25 | Myriad Genetics, Inc. | Compounds for treating viral infections |
| AR063546A1 (es) | 2006-11-03 | 2009-01-28 | Panacos Pharmaceuticals Inc | DERIVADOS DE TRITERPENO, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE INFECCIoN POR EL VIRUS VIH. |
| WO2008146305A2 (en) * | 2007-06-01 | 2008-12-04 | Council Of Scientific & Industrial Research | A pharmaceutical composition having virucidal and spermicidal activity |
| KR100941595B1 (ko) * | 2008-06-05 | 2010-02-11 | 주식회사 알앤엘바이오 | 바이러스 억제제로서 유용한 트리테르페노이드계 화합물 |
| CN102532245B (zh) * | 2011-12-31 | 2013-05-15 | 中国人民解放军第三军医大学 | 一种熊果酸衍生物及其制备方法 |
| EP3565527A4 (en) * | 2017-01-05 | 2019-12-18 | Regents of the University of California | CONTRIBUTIVE USE OF TRITER PENOIDS |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1415601A (en) * | 1973-03-14 | 1975-11-26 | Biorex Laboratories Ltd | Dihydrobetulinic acid derivatives |
| AU2001294953A1 (en) * | 2000-09-29 | 2002-04-08 | Regents Of The University Of Minnesota | Triterpenes having fungicidal activity against yeast |
-
2004
- 2004-09-27 KR KR1020067008088A patent/KR20060096147A/ko not_active Withdrawn
- 2004-09-27 US US10/949,875 patent/US20050148561A1/en not_active Abandoned
- 2004-09-27 CA CA002540160A patent/CA2540160A1/en not_active Abandoned
- 2004-09-27 AU AU2004276307A patent/AU2004276307A1/en not_active Abandoned
- 2004-09-27 EP EP04784972A patent/EP1675866A1/en active Pending
- 2004-09-27 WO PCT/US2004/031370 patent/WO2005030790A1/en not_active Ceased
- 2004-09-27 BR BRPI0415023-6A patent/BRPI0415023A/pt not_active IP Right Cessation
- 2004-09-27 JP JP2006528207A patent/JP2007506761A/ja not_active Withdrawn
-
2006
- 2006-03-14 IL IL174317A patent/IL174317A0/en unknown
- 2006-04-24 NO NO20061792A patent/NO20061792L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102248165B1 (ko) | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 | |
| Mathé et al. | L-nucleoside enantiomers as antivirals drugs: a mini-review | |
| de Clercq | Milestones in the discovery of antiviral agents: nucleosides and nucleotides | |
| AU763573B2 (en) | Thiadiazolyl urea or thiourea derivatives for antiviral treatment | |
| AU2007345952C1 (en) | Positively charged water-soluble prodrugs of 1H-imidazo[4, 5-c]quinolin-4-amines and related compounds with very high skin penetration rates | |
| JP2007506761A5 (https=) | ||
| US12167994B2 (en) | Vidofludimus for use in the treatment or prevention of viral diseases | |
| KR20200140274A (ko) | 4'-할로겐 함유 뉴클레오티드 및 뉴클레오시드 치료 조성물 및 이와 관련된 용도 | |
| CN107427529A (zh) | N4‑羟基胞苷和衍生物及与其相关的抗病毒用途 | |
| EA020488B1 (ru) | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний | |
| CA2632626A1 (en) | Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection | |
| JP2008519857A (ja) | ベツリン誘導体、これらの調製物、およびこれらの使用 | |
| JP2008505902A5 (https=) | ||
| IL298673A (en) | Methods for treating the corona virus infection | |
| JP2009525265A5 (https=) | ||
| US6911460B2 (en) | Antiviral agents and methods of treating viral infections | |
| JP2007506761A (ja) | 新規なトリテルペン誘導体、その製法および使用 | |
| ES2710915T3 (es) | Compuestos complejos de germanio, métodos para la producción de los mismos y fármacos | |
| US20190076467A1 (en) | Antiviral conjugates of polyanionic polymer and antiviral drug | |
| CN1413106A (zh) | 治疗炎症的6－甲氧基－2－萘乙酸前药 | |
| EP0979650A1 (en) | Antiviral agents | |
| JP2002540150A (ja) | ウイルス治療 | |
| JP2011513356A5 (https=) | ||
| WO2024193451A1 (en) | Triazine derivatives, method of making and method of using thereof | |
| US20230248678A1 (en) | Gemcabene for treating inflammation |